Multiple Sclerosis, Secondary Progressive Clinical Trials
2 recruiting trials for Multiple Sclerosis, Secondary Progressive. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Multiple Sclerosis, Secondary Progressive clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 / Phase 3 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Institute of Psychiatry and Neurology, Warsaw (1), Shirley Ryan AbilityLab (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Cladribine Subcutaneous Injection (drug, 1 trial), followed by 0.9% Chloride Injection Sodium, Acute Intermittent Hypoxia.
Track Multiple Sclerosis, Secondary Progressive trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
The purpose of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine versus placebo to stop inflammation and treat disease progression of...
Intermittent Hypoxia in Persons With Multiple Sclerosis
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Multiple Sclerosis, Secondary Progressive, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Multiple Sclerosis, Secondary Progressive, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Multiple Sclerosis, Secondary Progressive, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.